THE EFFECT OF TYPE II DIABETES MELLITUS TO TUBERCULOSIS TREATMENT OUTCOME : A SYSTEMATIC REVIEW
DOI:
https://doi.org/10.61841/fw448t55Keywords:
Type II Diabetes Mellitus, Tuberculosis, Treatment, EfficacyAbstract
Background: The converging epidemics of non-communicable disease like DM (DM) and an infectious disease like tuberculosis (TB) is a double burden. DM is increasing in the same population that is at high risk for developing TB.
Methods: By comparing itself to the standards set by the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020, this study was able to show that it met all of the requirements. So, the experts were able to make sure that the study was as up-to-date as it was possible to be. For this search approach, publications that came out between 2013 and 2023 were taken into account. Several different online reference sources, like Pubmed and SagePub, were used to do this. It was decided not to take into account review pieces, works that had already been published, or works that were only half done.
Result: In the PubMed database, the results of our search brought up 1199 articles, whereas the results of our search on SagePub brought up 892 articles. The results of the search conducted for the last year of 2013 yielded a total 30 articles for PubMed and 13 articles for SagePub. In the end, we compiled a total of 5 papers, 2 of which came from PubMed and 2 of which came from SagePub. We included five research that met the criteria.
Conclusion: In summary, DM plays a salient role among TBDM patients. Our results showed that even a doubling risk for poor treatment outcome would have substantial population impact—up to 25 of deaths in TB patients could be attributable to DM. These findings are not only important for lowmiddle income countries that have high TB incidence and high DM prevalence, but also important for high income countries with sub-populations that have higher risks of both conditions. Screening programmes for DM among TB patients should be implemented in primary care especially in regions that have high-incidence of TB. Further studies are needed to explore the optimal treatment plan and glycaemic control among TB-DM.
References
Krishna S, Jacob JJ. Diabetes Mellitus and Tuberculosis. Endotext. 2021;
Restrepo BI. Diabetes and Tuberculosis. Schlossberg D, editor. Microbiol Spectr [Internet]. 2016 Dec 23;4(6). Available from: https://journals.asm.org/doi/10.1128/microbiolspec.TNMI7-0023-2016
Faurholt-Jepsen D, Range N, Praygod G, Jeremiah K, Faurholt-Jepsen M, Aabye MG, et al. Diabetes is a strong predictor of mortality during tuberculosis treatment: A prospective cohort study among tuberculosis patients from Mwanza, Tanzania. Tropical Medicine and International Health. 2013 Jul;18(7):822–9.
Lee EH, Lee JM, Kang YA, Leem AY, Kim EY. Prevalence and Impact of Diabetes Mellitus Among Patients with Active Pulmonary Tuberculosis in South Korea. Lung. 2017;195(2):209–15.
Koesoemadinata RC, McAllister SM, Soetedjo NNM, Santoso P. Diabetes characteristics and long-term management needs in diabetic TB patients. Int J Tuberc Lung Dis. 2023;27(2):113–20.
Du J, Gao W, Ma Y, Zhong Q, Liang X. Treatment effect analysis of the standard regimen and the optimized regimen for retreatment pulmonary tuberculosis complicated with diabetes. CMAPH. 2015 Dec;38(12):886–91.
Chiang CY, Bai KJ, Lin HH, Chien ST, Lee JJ, Enarson DA, et al. The influence of diabetes, glycemic control, and diabetes-related comorbidities on pulmonary tuberculosis. PLoS One. 2015 Mar 30;10(3).
International Diabetes Federation. IDF Diabetes Atlas. Brussels. 2015.
Abdelbary BE, Garcia-Viveros M, Ramirez-Oropesa H, Rahbar MH, Restrepo BI. Tuberculosis-diabetes epidemiology in the border and non-border regions of Tamaulipas, Mexico. Tuberculosis (Edinb). 2016;124–34.
Jorgensen ME, Faurholt-Jepsen D. Is there an effect of glucose lowering treatment on incidence and prognosis of tuberculosis A systematic review. Curr Diab Rep. 2014;14(7):505.
Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, et al. Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Vol. 63, Clinical Infectious Diseases. Oxford University Press; 2016. p. 853–67.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Journal of Advanced Research in Medical and Health Science (ISSN 2208-2425)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
